
    
      This is a non-randomized trial phase 2 trial in which the drug Gilotrif will be administered
      at an oral dosage of 40 mg daily. This will continue until there is disease progression or
      severe toxicities. Patients will undergo a clinical exam every 4 weeks as well as have blood
      collected. Radiographic scans will be done every 8 weeks.
    
  